Chimeric Therapeutics (ASX:CHM) Accounts Payable : A$6.72 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Accounts Payable?

Chimeric Therapeutics's Accounts Payable for the quarter that ended in Dec. 2023 was A$6.72 Mil.

Chimeric Therapeutics's quarterly Accounts Payable increased from Dec. 2022 (A$3.41 Mil) to Jun. 2023 (A$7.41 Mil) but then declined from Jun. 2023 (A$7.41 Mil) to Dec. 2023 (A$6.72 Mil).

Chimeric Therapeutics's annual Accounts Payable increased from Jun. 2021 (A$2.04 Mil) to Jun. 2022 (A$4.70 Mil) and increased from Jun. 2022 (A$4.70 Mil) to Jun. 2023 (A$7.41 Mil).

Chimeric Therapeutics Accounts Payable Historical Data

The historical data trend for Chimeric Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Accounts Payable Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Accounts Payable

2.04

4.70

7.41

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable	Get a 7-Day Free Trial			4.33	4.70	3.41	7.41	6.72

Chimeric Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Chimeric Therapeutics Accounts Payable Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

CHMMF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines